Key Highlights

  • Anatara's GaRP Phase II trial in irritable bowel syndrome did not achieve statistical significance on its primary efficacy endpoint and has been formally closed out.
  • The net loss for the year to 30 June 2026 was A$933,230, down 52 per cent from A$1,954,702.
  • Auditor Grant Thornton issued an unqualified opinion with an emphasis of matter on going concern.

Anatara Lifesciences (ASX:ANR) has spent the past year scaling back its operations after a clinical setback. Its Annual Report for the year to 30 June 2026, lodged on 18 August 2026, shows a much lower cash burn than a year earlier, but also records a gastrointestinal trial that missed its primary efficacy endpoint, an obesity program on hold and an auditor's emphasis of matter on going concern.

What the company does

Anatara develops evidence-based products for gastrointestinal health. Its portfolio has included Gastrointestinal ReProgramming (GaRP), aimed at chronic gut conditions, and Detach, a treatment for diarrhoea in piglets. The annual report describes the current focus as the GaRP product and an anti-obesity project.

GaRP trial outcome

According to the annual report, the GaRP Phase II trial in irritable bowel syndrome did not achieve statistical significance on its primary efficacy endpoint, the overall IBS Symptom Severity Score, and the trial has been formally closed out. The result is a clinical setback rather than a step towards regulatory approval or market entry. In June 2023, a company update had said the trial would continue after a preliminary look at the first 31 participants, with a data safety monitoring board supporting the protocol. That update did not include efficacy results.

Anti-obesity project

The report says pre-clinical results for the candidate compound, referred to as AOC, showed some activity in limiting weight regain, but mechanism-of-action work was inconclusive on endogenous GLP-1 levels. A planned first-in-human Phase 1 study has been placed on hold.

Financial position

The net loss for the year was A$933,230, down 52 per cent from A$1,954,702. General and administrative expenses were A$973,003 and Research and Development costs A$280,504, compared with R&D costs of A$1,603,422 in the prior year. R&D tax incentive income fell to A$318,402 from A$969,456, and the operating cash outflow dropped to A$339,239 from A$2,271,997.

Cash at 30 June 2026 was A$470,917, up from A$101,356, and net Assets were A$711,538. The increase came from a Placement of 100 million shares at A$0.012, which raised A$1.2 million before costs and lifted the number of shares on issue to 315,950,765. Tranche 2 placement shares were issued on 26 November 2025.

The auditor, Grant Thornton, issued an unqualified opinion with an emphasis of matter on going concern. The directors state that meeting the company's obligations depends on raising additional capital, and any such raising would dilute existing holders.

Governance changes

Dirk van Dissel joined the board as a non-executive director in September 2025. Jonathan Lindh resigned as a non-executive director but remains company secretary, and Chief Development Officer Simon Erskine resigned on 13 May 2026. On 24 August 2026, the company Issued Shares on the conversion of performance rights.

Risks

The main risks are the absence of a validated lead asset following the GaRP result, the early stage of the obesity compound and the company's reliance on small Capital raisings.

The Bottomline

Anatara is now operating on a far smaller cost base, with cash of under half a million dollars at year end and its two main programs either closed or paused. The quarterly Appendix 4C lodged on 31 July 2026, and any capital raising the directors pursue, will show how the company intends to proceed.